VBC Market Dynamics
Expert articles and analysis related to vbc market dynamics.
AI Summary — Last 30 Days
VBC market activity is concentrating around two pressure points: Medicare Advantage payment integrity and risk adjustment volatility, and Medicaid affordability for high-cost therapies. MA plans are aggressively contesting CMS’ 2027 Star Ratings methodology—Aetna says more than $2B is at stake and Centene estimates a $448M hit—while KFF data show 4.3M beneficiaries face MA or Part D plan terminations at the end of 2026, signaling continued benefit redesign, market exits, and network disruption for providers tied to MA value-based contracts (Aetna lawsuit; KFF plan terminations). At the same time, Privia’s $36M acquisition of American Choice Healthcare’s MSSP business points to continued consolidation around ACO infrastructure, while Health Affairs’ focus on GLP-1 access under the BALANCE Model and social risk adjustment underscores a broader shift: VBC stakeholders are pushing for payment models that can absorb expensive therapeutics and account for patient complexity without penalizing providers serving higher-risk populations.
Related Articles
OKC's largest private employer Integris set to join Kaiser-backed Risant
OKC's largest private employer Integris set to join Kaiser-backed Risant The Oklahoman
AHA urges court to reject drug industry intervention in 340B rebate program case
AHA urges court to reject drug industry intervention in 340B rebate program case American Hospital Association
INTEGRIS Health in Oklahoma to be acquired by Risant Health under new agreement
INTEGRIS Health in Oklahoma to be acquired by Risant Health under new agreement KOKH
Integris Health to Become Third Health System to Join Kaiser-Backed Risant Health
Integris Health to Become Third Health System to Join Kaiser-Backed Risant Health HCI Innovation Group
Price of new drugs up 35% since 2022: 6 things hospital leaders should know
Price of new drugs up 35% since 2022: 6 things hospital leaders should know Becker's Hospital Review
The U.S. Pays Triple What Other Countries Pay for Drugs. Here’s What the Evidence Says About Fixing It.
The U.S. Pays Triple What Other Countries Pay for Drugs. Here’s What the Evidence Says About Fixing It. AcademyHealth
INTEGRIS Health set to join Kaiser Permanente subsidiary Risant Health
INTEGRIS Health set to join Kaiser Permanente subsidiary Risant Health KFOR
Analysis finds net launch price for new prescription drugs climbed 35% from 2022 to 2025
Analysis finds net launch price for new prescription drugs climbed 35% from 2022 to 2025 American Hospital Association
New ICER report suggests drug launch prices are outpacing their worth
The median list price of drugs at launch rose 24% from 2022 to 2025, and the net prices of those drugs rose even higher, according to a new report from the Institute for Clinical and ...
STAT+: Launch prices for new medicines dipped slightly last year but remain high, analysis finds
The median net price for 202 newly launched medicines rose by 35%, to $257,000 last year from $173,000 in 2022.